Mono

Mono (Shanghai) Biotechnology, commonly known as Mono Bio, is a clinical-stage biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary platform for mRNA design and lipid nanoparticle (LNP) delivery to address challenges in infectious diseases, oncology, and rare genetic disorders. Its lead program is an mRNA vaccine for COVID-19, which has progressed through clinical trials in China and international markets. Beyond vaccines, Mono is actively expanding its pipeline into personalized cancer vaccines and protein replacement therapies. The company is recognized for its end-to-end capabilities, spanning from early-stage sequence optimization to large-scale GMP manufacturing.